Abstract 2981: Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models

For full functionality of ScholarMagic it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

up vote 0 down vote

Abstract 2981: Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models

C Brignole, et al. (2023)
Cancer Research

up vote 0 down vote

There is no summary for this article.

Medical and Health Science

citation rate

Insert citation
	Comments
	Share
	Details
Shortlist	Citation

Abstract

Comments are visible to all users.

Your personal notes related to this publication. These notes are only visible to you, will save automatically, and will be here when you come back.

Authors:	C Brignole, V Bensa, E Calarco, E Giusto, E Ciampi, P Perri, MV Corrias, S Astigiano, M Cilli, D Loo, E Bonvini, F Pastorino, M Ponzoni
Year published:	2023
DOI:	10.1158/1538-7445.am2023-2981
Full-text available:	Yes
Journal:	Cancer Research
Publisher:	American Association for Cancer Research (AACR)

Report an issue